Bicycle Therapeutics reports initial Duravelo-2 Phase 2 data in metastatic urothelial cancer

• Bicycle Therapeutics flagged initial data from its randomized Phase 2 Duravelo-2 trial of Nectin-4 drug conjugate zelenectide pevedotin in metastatic urothelial cancer, with results set for presentation at the 2026 ASCO Annual Meeting.
• The dose-optimized regimen in combination with Merck’s Keytruda produced responses broadly in line with published first-line standards of care, supporting continued development in an increasingly competitive setting.
• The company highlighted a potentially differentiated tolerability profile versus published standard-of-care benchmarks, with fewer treatment-limiting side effects such as skin toxicity and peripheral neuropathy.
• Updated Phase 1 Duravelo-1 findings will also be presented at ASCO, pointing to clinically meaningful disease control and progression outcomes in cisplatin-ineligible patients treated with the combination.
• Additional results from the randomized Phase 2 program are expected in 2H 2026, a key catalyst for next-step partnering and registrational planning.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicycle Therapeutics plc published the original content used to generate this news brief via Business Wire (Ref. ID: 202605211700BIZWIRE_USPR_____20260521_BW033084) on May 21, 2026, and is solely responsible for the information contained therein.